Skip to content
Alert Sign COVID-19 Updates: New Visitor Guidelines & Vaccine Update Close Alert Box
Hackensack UMC logo
  • GIVE NOW
  • 1-844-HMH-WELL
  • Find a Doctor
  • About
  • Location
  • Team
  • News
  • Services
  • Research
  • Donate

Clinical Trials

Find a DoctorOur LocationsAwards and Accreditation

Home  › Research  ›  Trials

Search for:

ROSY-O: Roll over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit from Continued Treatment


MERCK MK7902-001-01 A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)


MERCK MK7902-001-01 A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)


Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy


A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer


Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen


A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer


A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer, MK-3475 KN775


A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)


A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer


View all types of trials

Types of Cancer / Trials

  • All
  • Breast
  • Breast-Surgical Oncology
  • Gastrointestinal
  • Genito-Urinary
  • Gynecologic
  • Head and Neck
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Neuro-oncology
  • Phase 1
  • Phase 1 (GI)
  • Phase 1 (L)
  • Phase 1 (Thoracic)
  • Skin and Soft Tissue
  • Thoracic (Lung)
  • Transplant

Recently Added Trials

  • A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
  • A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma.
  • A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma
  • A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
  • A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of NivolumabVersus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human EpidermalGrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

© 2021 Hackensack Meridian Health

  • About Us
  • Careers
  • Classes & Events
  • Contact Us
  • Donate
  • Financial Practices
  • Patients & Visitors
  • Privacy
  • Terms & Conditions